What is Theravance Biopharma's cash ratio?

Theravance Biopharma (TBPH) reported cash ratio of 9.1× in Q1 2026.

How has Theravance Biopharma's cash ratio changed year-over-year?

Theravance Biopharma's cash ratio increased by 158.2% year-over-year, from 3.5× to 9.1×.

What is the long-term trend for Theravance Biopharma's cash ratio?

Over 5 years (2020 to 2025), Theravance Biopharma's cash ratio has grown at a 46.0% compound annual growth rate (CAGR), from 0.7× to 4.4×.

What does cash ratio mean?

Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.

Theravance Biopharma TBPH Cash ratio

Cash ratio at other companies

Zevra Therapeutics, Inc.ZVRA

2×+0.6×

LQD

Liquidia CorporationLQDA

1.5×-1.3×

Royalty PharmaRPRX

1.1×+0.2×

United TherapeuticsUTHR

2.1×-0.5×

Aurinia PharmaceuticalsAUPH

0.5×-0.5×

PrecigenPGEN

0.4×+0.1×

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$890.32M+67.5%

Enterprise value$642.72M+37.0%

P/E7.8×—

P/S8.1×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Calculated from Theravance Biopharma’s reported figures.

cash and equivalents/total current liabilities=9.1×

Based on the most recent quarter.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's cash ratio?: Theravance Biopharma (TBPH) reported cash ratio of 9.1× in Q1 2026.
How has Theravance Biopharma's cash ratio changed year-over-year?: Theravance Biopharma's cash ratio increased by 158.2% year-over-year, from 3.5× to 9.1×.
What is the long-term trend for Theravance Biopharma's cash ratio?: Over 5 years (2020 to 2025), Theravance Biopharma's cash ratio has grown at a 46.0% compound annual growth rate (CAGR), from 0.7× to 4.4×.
What does cash ratio mean?: Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.